

From: Dorsey, Michael </O=MAIL/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=MICHAEL.DORSEY>
To: Saakyan, Violet
Sent: 7/23/2015 2:41:36 PM
Subject: RE: HYDROCODONE/IBUPROFEN - new award?

Violet,

Question: How did SOM's not stop this order? It's a CII...

Mike Dorsey
Director, National Accounts

Michael.Dorsey@actavis.com

262.377.0874 O 262.421.4636 F

414.759.8312 C



This message and its attachments are intended for the named addressee only, and may contain confidential, proprietary or legally privileged information. No confidentiality or privilege is waived or lost by any mistransmission. If you have by coincidence or mistake received this email and its attachments, please immediately delete it and all copies of it from your system, destroy any hard copies of it and notify the sender. You must not, directly or indirectly, use, disclose, distribute, print or copy any part of this message or its attachments if you are not the intended recipient. Please note that the sender of this e-mail and its attachments is solely responsible for its content if it does not concern the operations of Actavis, Inc. or its affiliates.

From: Saakyan, Violet
Sent: Thursday, July 23, 2015 10:19 AM
To: Dorsey, Michael
Subject: FW: HYDROCODONE/IBUPROFEN - new award?

We are scrambling to build the inventory. 90 days lead time puts us/them around 8/22. Can we delay this a bit? If need be.

Also ABC already pulled 6K – why are doing stuff like this?!?!


From: Dorsey, Michael
Sent: Wednesday, July 22, 2015 4:56 PM
To: Asea, Tara; Saakyan, Violet; Giannone, Anthony; #GenericContracts
Cc: #GenericPricing; Cipkins, Ann; Padilla, Edgar
Subject: RE: HYDROCODONE/IBUPROFEN - new award?

It should be Walgreens – see attached.

Did this get uploaded in Demand Forecast?

Mike Dorsey
Director, National Accounts

Michael.Dorsey@actavis.com



Highly Confidential

Acquired_Actavis_00254144

P-02415 _ 00001

262.377.0874 O 262.421.4636 F

414.759.8312 C



This message and its attachments are intended for the named addressee only, and may contain confidential, proprietary or legally privileged information. No confidentiality or privilege is waived or lost by any mistransmission. If you have by coincidence or mistake received this email and its attachments, please immediately delete it and all copies of it from your system, destroy any hard copies of it and notify the sender. You must not, directly or indirectly, use, disclose, distribute, print or copy any part of this message or its attachments if you are not the intended recipient. Please note that the sender of this e-mail and its attachments is solely responsible for its content if it does not concern the operations of Actavis, Inc. or its affiliates.

From: Asea, Tara
Sent: Wednesday, July 22, 2015 4:51 PM
To: Saakyan, Violet; Giannone, Anthony; Dorsey, Michael; #GenericContracts
Cc: #GenericPricing; Cipkins, Ann; Padilla, Edgar
Subject: RE: HYDROCODONE/IBUPROFEN - new award?

I just checked and wasn't able to locate any new awards. Maybe Pricing knows?

Thanks,

Tara B. Asea

Senior Manager, Contract Admin – US Generics
Morris Corporate Center III
400 Interpace Parkway
Parsippany, NJ 07054
Ph: 862-261-7255
Fax: 862-261-7934
Tara.Asea@actavis.com



From: Saakyan, Violet
Sent: Wednesday, July 22, 2015 3:40 PM
To: Giannone, Anthony; Dorsey, Michael; #GenericContracts
Cc: #GenericPricing; Cipkins, Ann; Padilla, Edgar
Subject: HYDROCODONE/IBUPROFEN - new award?

Contracts,

Has there been any new awards on this SKU? ABC is buying heavy this month. Sales are not showing in the market cube and there is nothing in our trackers.

NDC	PRODUCT DESCRIPTION	CONTRACT ENTITY	201501	201502	201503	201504	201505	201506	201507
			Direct Sales Quantity	Direct Sales Quantity	Direct Sales Quantity	Direct Sales Quantity	Direct Sales Quantity	Direct Sales Quantity	Direct Sales Quantity
62037052401	HYDROCODONE/IBUPROFEN 7.5/200MG TAB 100	AMERISOURCEBERGEN CORP	100	120	132	216	252	300	6060

Highly Confidential

Acquired_Actavis_00254145

P-02415 _ 00002

Thank you,
Violet

This e-mail, including any attachments, is meant only for the intended recipient of the transmission, and may be a confidential or privileged communication. If you received this e-mail in error, any review, use, dissemination, distribution, or copying of this e-mail is strictly prohibited. Please notify us immediately of the error by return e-mail and please delete this message from your system. Thank you in advance for your cooperation.

Highly Confidential

Acquired_Actavis_00254146

P-02415 _ 00003